Oncology

Piramal Healthcare strives to become a leader in oncology by consistently discovering and developing novel therapies that may improve and extend the lives of people living with cancer.  Cancer is a complex group of diseases fueled by many underlying mechanisms. Research and development at the Piramal Healthcare Research Centre is built on recent discoveries in molecular genomics, rational drug design and state-of-the-art drug discovery technologies. To support these efforts, the Company makes considerable investments in technologies and expertise, both internally and externally.  The Oncology Therapeutic Area franchise seeks to build successful partnerships by identifying areas of collaboration to benefit the cancer patient.

By partnering with members of the oncology community, the Company effectively expands research and development.  The robust R&D program has enabled the Company to advance a broad range of innovative therapies in development, especially in various phases of clinical trials. The Piramal Healthcare research pipeline, one of the broadest and deepest oncology pipelines in the Indian industry, currently includes two small molecules PL225B and P7170 in preclinical development; three small molecules P276, P1446 and P2745 in different stages of clinical trials; a large portfolio of development candidates; and a productive drug discovery engine.

Selected publications:

1. SM Manohar, AA Padgaonkar, A Jalota-Badhwar, SV Rao and KS Joshi. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1 alpha and induces G2/M arrest under hypoxia in prostate cancer cells. Prostate Cancer and Prostatic Diseases, 2011, 1-3.
2. Sonal M. Manohar, Maggie J. Rathos, Vinay Sonawane, Shalini V. Rao and Kalpana S. Joshi. Cyclin-dependent kinase inhibitor, P-276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leukemia Research, 2011, 35, 821-830.
3. Sonal Manohar, Amol Padgaonkar, Archana J. Badhwar, Vinay Sonawane, Maggie J. Rathos, Sanjay Kumar & Kalpana S. Joshi. A novel inhibitor of hypoxia-inducible factor-1alpha P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells. BMC Cancer, 2011, 11:338, 1-10.
4. Sunil Kumar Malonia, Surajit Sinha, Pavithra Lakshminarasimhan, Kamini Singh, Archana Jalota-Badhwar, Shravanti Rampalli, Ruchika Kaul-Ghanekar, Samit Chattopadhyay. Gene regulation by SMAR1: Role in cellular homeostasis and cancer. Biochimica et Biophysica Acta-Reviews on Cancer 2011, 1815:1.